Strong epidemiologic evidence showed that loss-of-function polymorphisms of FPR1 are positively associated with poor responses to chemotherapeutic drugs and an earlier mean age of cancer diagnosis (Sztupinszki et al., 2021) also in CRC patients. This evidence concerns the gene FPR1 and cancer.